In the Interim…

In the Interim...
Podcast Description
A podcast on statistical science and clinical trials.
Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
Podcast Insights
Content Themes
Explores Bayesian statistics, adaptive clinical trial designs, and innovative methodologies to tackle medical challenges, with episodes featuring in-depth discussions such as the transformative impact of platform trials during the COVID pandemic and regulatory navigation in adaptive trials.

A podcast on statistical science and clinical trials.
Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
In this episode of “In the Interim…”, Dr. Scott Berry interviews Dr. Derek Angus, Distinguished Professor and Chair of Critical Care Medicine at the University of Pittsburgh and Senior Editor at JAMA. The discussion addresses the decades-long controversy surrounding steroid use in community-acquired pneumonia (CAP) and sepsis. The episode delivers a chronological assessment of the evidence base—summarizing trial results from pivotal studies, including CAPE COD, REMAP-CAP, ADRENAL, and multiple French trials led by Dr. Djillali Annane. Dr. Angus analyzes why discrepancies persist in outcomes, clinical recommendations, and international guidelines, and underscores the challenge of heterogeneous treatment effects. The episode closes with an argument for adaptive trial designs, Bayesian inference, and embedded randomization within learning health systems as critical tools for clarifying complex response patterns and improving patient care.
Key Highlights
- Historical evolution of clinical trials studying steroid regimens for CAP/sepsis
- Review of CAPE COD, REMAP-CAP, ADRENAL, and Annane-led French trials showing conflicting signals.
- Discussion of persistent heterogeneity in trial populations, interventions, and endpoints.
- Identification of methodological limitations—control contamination, endpoint definitions, varying inclusion criteria.
- Exploration of Bayesian and adaptive trial design, and operationalization of learning health systems to resolve evidence gaps.
For more, visit: https://www.berryconsultants.com/

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.